Consistent, Ongoing Care Reduced Anxiety and Depression in IBD: What 12 Randomised Trials Found

Living with inflammatory bowel disease means managing an illness that is unpredictable, often invisible to others, and closely linked to mental health. Anxiety and depression are not uncommon alongside IBD, and the NHS notes that these difficulties frequently accompany flares, surgery, and ongoing treatment (NHS, Living with UC). A new meta-analysis published in 2026 asked a practical question: does having a consistent, structured care team make a measurable difference to psychological wellbeing?

What the Researchers Did

Huang and colleagues searched five databases for randomised controlled trials published from database inception through March 2026. They identified 12 trials involving 1,246 participants with IBD, all evaluating programmes described as providing continuity of patient care (Huang XR et al., PeerJ, 2026). The trials measured outcomes including disease-specific quality of life (using the IBD Questionnaire and the SF-36), anxiety scores, and depression scores. The researchers pooled the results using standard statistical methods and assessed the risk of bias in each trial using Cochrane tools.

What "Continuity of Care" Means in These Trials

Across the included studies, continuity of care typically referred to structured programmes in which patients had ongoing, scheduled contact with a named clinical team, rather than ad hoc appointments or standard outpatient review. This could involve a dedicated IBD nurse, a regular telephone or in-person follow-up schedule, or a nurse-led care coordination programme. The specific formats varied between trials, which is relevant to understanding the results below.

What the Analysis Found

On anxiety: Pooled data from the 12 trials showed that continuity of care was associated with a statistically significant reduction in anxiety scores compared with standard care (standardised mean difference = -1.98, 95% confidence interval: -2.40 to -1.55, p < 0.00001). An SMD of approximately -2 is a large effect size by conventional benchmarks.

On depression: The analysis found a similar significant reduction in depression scores (SMD = -1.82, 95% CI: -2.67 to -0.98, p < 0.0001).

On quality of life: Both the IBD Questionnaire and SF-36 scores improved in the continuity of care groups across the included trials.

On disease recurrence: Here the picture was different. Continuity of care did not produce a statistically significant difference in disease recurrence rates (RR = 0.94, 95% CI: 0.53 to 1.67, p = 0.83). This is an important finding: psychological benefits and disease activity are not the same thing, and the former can be meaningfully improved without necessarily reducing the latter.

The Important Caveats

The authors themselves flag that this meta-analysis has a significant limitation: extremely high statistical heterogeneity between the 12 included trials. Heterogeneity in a meta-analysis reflects the degree to which the trials varied in their populations, intervention designs, outcome measures, and follow-up periods. Very high heterogeneity means the pooled estimate is harder to interpret with confidence, because it is averaging across programmes that may have worked quite differently in quite different patient groups.

Because of this, the authors rated the overall evidence quality as moderate, not high. The large effect sizes on anxiety and depression should be read in this context. The signal is consistent and statistically strong, but the individual trials contributing to it were varied enough that the pooled number cannot be read as a precise prediction of what any one care programme will achieve.

What This Means for Patients

This meta-analysis adds to a growing body of evidence that how IBD care is organised, and not just which treatments are prescribed, matters for the people receiving it. The finding that consistent, ongoing contact with a care team was associated with lower anxiety and depression is meaningful and patient-centred. It also aligns with what many people with IBD describe in their own accounts: that having a named person to contact, a regular review, and continuity of relationship makes the illness feel less isolating.

The fact that recurrence rates were not significantly affected is also worth noting. Mental health and disease activity are distinct. Improving one does not automatically change the other, and both deserve attention in IBD management.

Please speak with your doctor or care team if anxiety or depression is affecting your daily life with IBD. Your gastroenterologist, specialist nurse, or GP can assess what support is available through your IBD service, refer you to psychological therapies, or review whether your physical disease management can be optimised. The findings summarised here come from a moderate-quality meta-analysis of 12 trials and cannot be applied to any individual situation without a proper clinical assessment.